Open AccessA single arm, investigator initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
Author(s) -
Rishi P. Singh,
Sunil Srivastava,
Justis P. Ehlers,
Fabiana Caetano Martins Silva e Dutra,
Rumneek Bedi,
Andrew Schachat,
Peter K. Kaiser
Publication year - 2017
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s116038
Subject(s) - medicine , ranibizumab , macular degeneration , aflibercept , tolerability , bevacizumab , ophthalmology , adverse effect , surgery , chemotherapy
[This corrects the article on p. 1759 in vol. 9, PMID: 26445522.].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom